ClinicalTrials.Veeva

Menu
H

Houston Clinical Trials, LLC | Bellaire, TX

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rapastinel
SDX
dexmethylphenidate
Ecopipam
BI 1569912
Serdexmethylphenidate
d-MPH
EYE103
Psilocybin
Seltorexant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 22 total trials
Locations recently updated

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201.All participants in the study w...

Enrolling
BRVO - Branch Retinal Vein Occlusion
Diabetic Macular Edema (DME)
Drug: EYE201

The is a multicenter, dose-optimized, open-label, safety/ tolerability and pharmacokinetic (PK) study with Azstarys® in children 4 and 5 years of age...

Active, not recruiting
Attention Deficit/Hyperactivity Disorder
Drug: Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Locations recently updated

EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active...

Enrolling
Diabetic Macular Edema (DME)
Drug: EYE103
Drug: Ranibizumab

This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is t...

Enrolling
Depressive Disorder, Major
Drug: Placebo matching BI 1569912
Drug: BI 1569912
Locations recently updated

This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did...

Enrolling
Depressive Disorder, Major
Drug: BI 1569912
Drug: Placebo

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Enrolling
Treatment Resistant Depression
Drug: Psilocybin

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18...

Enrolling
Acute Treatment of Migraine
Drug: Rimegepant (PF-07899801)

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling
Depressive Disorder, Major
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug: Placebo

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling
Pediatric Migraine
Drug: Rimegepant/BHV3000
Drug: Matching placebo

Trial sponsors

Allergan logo
E
AbbVie logo
Boehringer Ingelheim logo
C
E
Pfizer logo
Allergan logo
C
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems